阿帕替尼治疗放射性碘难治性与高度侵袭性甲状腺癌的研究进展

doi:10.16139/j.1007-9610.2021.06.021

摘要/Abstract

中图分类号:

R736.1

詹灵(综述), 邱伟华(审校). 阿帕替尼治疗放射性碘难治性与高度侵袭性甲状腺癌的研究进展[J]. 外科理论与实践, 2021, 26(06): 564-567.

ZHAN Ling, QIU Weihua. Progress in study on apatinib in treatment of both radioactive iodine refractory and more aggressive thyroid carcinoma[J]. Journal of Surgery Concepts & Practice, 2021, 26(06): 564-567.

参考文献 29

[30]	Feng H, Cheng X, Kuang J, et al. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer[J]. Cell Death Dis, 2018, 9(10):1030.
[31]	Meng X, Wang H, Zhao J, et al. Apatinib inhibits cell proliferation and induces autophagy in human papillary thyroid carcinoma via the PI3K/Akt/mTOR signaling pathway[J]. Front Oncol, 2020, 10:217.
[32]	Peng QX, Han YW, Zhang YL, et al. Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma[J]. Oncotarget, 2017, 8(32):52813-52822.
[33]	Liu S, Wu F, Zhang Y, et al. Apatinib combined with radiotherapy enhances antitumor effects in an in vivo nasopharyngeal carcinoma model[J]. Cancer Control, 2020, 27(1):1073274820922553.
[34]	Li F, Zhu T, Cao B, et al. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance[J]. Eur J Cancer, 2017, 84:184-192.
[35]	Hu Y, Zhou N, Wang R. Apatinib strengthens the anti-tumor effect of cisplatin in thyroid carcinoma through downregulating VEGFR2[J]. J BUON, 2021, 26(2):613-619.
[36]	Tong XZ, Wang F, Liang S, et al. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells[J]. Biochem Pharmacol, 2012, 83(5):586-597.
[37]	Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters[J]. Cancer Res, 2010, 70(20):7981-7991.
[1]	Jin Y, van Nostrand D, Cheng L, et al. Radioiodine refractory differentiated thyroid cancer[J]. Crit Rev Oncol Hematol, 2018, 125:111-120.
[2]	Cai S, Deng H, Chen Y, et al. Treatment of medullary thyroid carcinoma with apatinib: a case report and literature review[J]. Medicine (Baltimore), 2017, 96(50):e8704.
[3]	Cheng L, Jiao Q, Jin Y, et al. Initial therapy of advanced anaplastic thyroid cancer via targeting VEGFR-2: a case report[J]. Onco Targets Ther, 2019, 12:10495-10500.
[4]	Ibrahimpasic T, Ghossein R, Shah JP, et al. Poorly differentiated carcinoma of the thyroid gland: current status and future prospects[J]. Thyroid, 2019, 29(3):311-321.
[5]	Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers[J]. J Clin Endocrinol Metab, 2009, 94(5):1493-1499.
[6]	Guleng B, Tateishi K, Ohta M, et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner[J]. Cancer Res, 2005, 65(13):5864-5871.
[7]	Klein M, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma[J]. J Endocrinol, 1999, 161(1):41-49.
[8]	Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940):319-328.
[9]	Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7):621-630.
[10]	Li J, Qin S, Xu J, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase Ⅱtrial[J]. J Clin Oncol, 2013, 31(26):3219-3225.
[11]	Xiao J, Liang J, Zhang W, et al. Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies[J]. Exp Ther Med, 2020, 20(3):1961-1966.
[12]	Scott LJ. Apatinib: a review in advanced gastric cancer and other advanced cancers[J]. Drugs, 2018, 78(7):747-758.
[13]	Zhou Y, Zhang W, Tang F, et al. A case report of apatinib in treating osteosarcoma with pulmonary metastases[J]. Medicine (Baltimore), 2017, 96(15):e6578.
[14]	Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase Ⅱtrial[J]. Clin Cancer Res, 2021, 27(4):1003-1011.
[15]	Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase Ⅲtrial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016, 34(13):1448-1454.
[16]	Zhang S. Problematic analysis and inadequate toxicity data in phase Ⅲapatinib trial in gastric cancer[J]. J Clin Oncol, 2016, 34(31):3821.
[17]	Hu X, Cao J, Hu W, et al. Multicenter phase Ⅱstudy of apatinib in non-triple-negative metastatic breast cancer[J]. BMC Cancer, 2014, 14:820.
[18]	Wu F, Zhang S, Xiong A, et al. A phase Ⅱclinical trial of apatinib in pretreated advanced non-squamous non-small-cell lung cancer[J]. Clin Lung Cancer, 2018, 19(6):e831-e842.
[19]	Zhang Y, Deng X, Ding Z, et al. Preoperative neoadjuvant targeted therapy with apatinib for inoperable diffe-rentiated thyroid cancer: a case report[J]. Medicine (Baltimore), 2021, 100(12):e25191.
[20]	Lin Y, Wang C, Gao W, et al. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer[J]. Oncotarget, 2017, 8(26):42252-42261.
[21]	Chen K, Gao Y, Shi F, et al. Apatinib-treated advanced medullary thyroid carcinoma: a case report[J]. Onco Targets Ther, 2018, 11:459-463.
[22]	Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Sta-ging System for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why?[J]. Thyroid, 2017, 27(6):751-756.
[23]	Sugitani I, Miyauchi A, Sugino K, et al. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC Research Consortium of Japan cohort study of 677 patients[J]. World J Surg, 2012, 36(6):1247-1254.
[24]	De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004, 60(4):1137-1143.
[25]	Niu Y, Ding Z, Deng X, et al. A novel multimodal therapy for anaplastic thyroid carcinoma: ¹²⁵I seed implantation plus apatinib after surgery[J]. Front Endocrinol (Lausanne), 2020, 11:207.
[26]	Chen W, Li Z, Zheng Z, et al. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: a single-center retrospective study[J]. Cancer Med, 2020, 9(16):5899-5907.
[27]	Lin YS, Zhang X, Wang C, et al. Long-term results of phase Ⅱtrial of apatinib for progressive radioiodine refractory differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2021, 106(8):e3027-e3036.
[28]	Zhang X, Wang C, Lin Y. Pilot dose comparison of apatinib in Chinese patients with progressive radioiodine-refractory differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2018, 103(10):3640-3646.
[29]	Jin Z, Cheng X, Feng H, et al. Apatinib inhibits angiogenesis via suppressing Akt/GSK3β/ANG signaling pathway in anaplastic thyroid cancer[J]. Cell Physiol Biochem, 2017, 44(4):1471-1484.

阿帕替尼治疗放射性碘难治性与高度侵袭性甲状腺癌的研究进展

Progress in study on apatinib in treatment of both radioactive iodine refractory and more aggressive thyroid carcinoma

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	贺文, 顾建华, 邢戌健, 翁子毅, 费健. 术中发现气管憩室2例病例报告并文献复习[J]. 外科理论与实践, 2023, 28(04): 383-387.
[2]	吴春晓, 顾凯, 庞怡, 鲍萍萍, 王春芳, 施亮, 向詠梅, 龚杨明, 窦剑明, 吴梦吟, 付晨, 施燕. 2016年上海市甲状腺癌发病和死亡情况与2002—2016年间变化趋势分析[J]. 外科理论与实践, 2022, 27(01): 58-65.
[3]	唐娟, 刘志艳. 第4版WHO分化型甲状腺癌病理分类及其进展[J]. 外科理论与实践, 2021, 26(06): 504-509.
[4]	姚京, 李晨, 田文. 甲状腺癌的规范诊治[J]. 外科理论与实践, 2021, 26(06): 467-471.
[5]	黄乃思, 陈嘉莹, 嵇庆海, 王宇. 靶向药物时代局部晚期甲状腺癌的新辅助治疗[J]. 外科理论与实践, 2021, 26(06): 493-496.
[6]	王卓颖, 史苑, 郭凯, 钱凯. 青少年分化型甲状腺癌的诊治：从陌生到规范[J]. 外科理论与实践, 2021, 26(06): 497-499.
[7]	赖丽梅, 周建桥. 超声引导下射频消融术在甲状腺结节治疗中的应用进展[J]. 诊断学理论与实践, 2021, 20(02): 216-220.
[8]	周伟, 陈易来, 詹维伟. 细针穿刺洗脱液中甲状腺球蛋白检测在诊断分化型甲状腺癌淋巴结转移中的应用进展[J]. 诊断学理论与实践, 2020, 19(04): 339-343.
[9]	王星, 汪蓉晖, 张桂萍, 董屹婕, 周伟, 詹维伟. 10 388个甲状腺结节行超声引导下细针抽吸活检的甲状腺癌各亚型诊断准确率的10年研究[J]. 诊断学理论与实践, 2020, 19(04): 359-363.
[10]	张斌忠, 董来荣, 何春华, 王胤达. 阿帕替尼联合替吉奥化疗对照SOX方案一线治疗晚期胃癌的临床研究[J]. 外科理论与实践, 2020, 25(04): 341-343.
[11]	张倜, 杨雪娇. 肝癌靶向治疗相关高血压的发生与处置[J]. 外科理论与实践, 2020, 25(01): 29-34.
[12]	顾耀耀, 倪雪君. 超声在甲状腺癌颈部淋巴结转移临床诊断中的实用价值[J]. 诊断学理论与实践, 2019, 18(06): 662-667.
[13]	杨迟晖, 张晶, 孟磊俊, 宫丽平, 常庆, 张泓, 曾乃燕. 对乳头状甲状腺癌临床分子靶标的筛选[J]. 诊断学理论与实践, 2019, 18(04): 402-411.
[14]	沈晓卉, 丁家增, 陈海珍, 崔昂, 陈曦. 甲状腺再次手术分析（附110例报告）[J]. 外科理论与实践, 2019, 24(01): 79-84.
[15]	黄海燕, 匡洁, 应夏洋, 陈曦, 严佶祺. Graves病合并甲状腺癌（附47例报告）[J]. 外科理论与实践, 2018, 23(06): 519-522.